Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

SAB Biotherapeutics, Inc. - Common Stock (NQ: SABS )

1.640 +0.010 (+0.61%)
Streaming Delayed Price Updated: 10:08 AM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 288
Open 1.630
Bid (Size) 1.500 (3)
Ask (Size) 1.650 (6)
Prev. Close 1.630
Today's Range 1.630 - 1.640
52wk Range 1.450 - 6.300
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SAB BIO to Participate in Upcoming Investor Conferences
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Why Is SAB BIO Stock Trading Lower On Tuesday?
SAB BIO's SAB-142 Phase 1 trial data supports its safety and pharmacodynamic activity, paving the way for a Phase 2b trial in T1D in 2025. 
Via Benzinga

Performance

YTD
-55.80%
-55.80%
1 Month
-0.61%
-0.61%
3 Month
-57.62%
-57.62%
6 Month
-40.69%
-40.69%
1 Year
-71.68%
-71.68%

More News

Read More
Gold Gains 1%; Boeing Shares Rise Following Q4 Results
Via Benzinga
Nasdaq Surges More Than 300 Points; Lockheed Martin Shares Dip After Q4 Results
Via Benzinga
Dow Gains Over 50 Points; General Motors Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SABS Stock Earnings: SAB Biotherapeutics Beats EPS for Q2 2024
Via InvestorPlace
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Appoints Lucy To as Chief Financial Officer
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
SAb Biotherapeutics Rebrands as SAB BIO
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces Departure of Chief Financial Officer
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
SABS Stock Earnings: SAB Biotherapeutics Misses EPS for Q1 2024
Via InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.